While a detailed understanding of the molecular machinery that controls DR4 and DR5 action in cancer cells is crucial for improving the efficiency of DR4- and/or DR5- activating agents in cancer treatment, and for selecting patients with tumours that are more amenable to this therapeutic approach, surprisingly little is known about the mechanisms that improve the sensitivity of cancer cells to these molecules. This evidence concerns the gene TNFRSF10A and neoplasm.